Highlights from a Presentation at the 32nd Annual Hawaii Dermatology SeminarTM. Waikoloa, Hawaii, March 1-7, 2008.
A supplement to Skin & Allergy News supported by an educational grant from OrthoNeutrogena..
This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News.
To view the supplement, click the image above.
James Q. Del Rosso, DO, MD
Clinical Associate Professor, Dermatology
University of Nevada School of Medicine
Las Vegas, Nevada
Touro University Nevada College of Osteopathic Medicine
Dermatology Residency Director
Valley Hospital Medical Center
Las Vegas, Nevada
Dr. Del Rosso has received grant/research support, has been a consultant, and has served on the speaker's bureau of OrthoNeutrogena, Medicis Pharmaceutical Corporation, Stiefel Laboratories, Inc., Ranbaxy Pharmaceuticals Inc., and Galderma Laboratories, L.P. In this supplement, Dr. Del Rosso will reference unlabeled/unapproved uses of sertaconazole 2% cream.
Superficial fungal infections can be caused by a broad spectrum of fungal pathogens including dermatophytes, yeasts, and molds and can usually be treated successfully with topical antifungal therapy. Diagnosis of superficial fungal infections is commonly based on location and characteristics of the lesions. However, care must be taken to differentiate fungal infections caused by dermatophytes from those caused by yeasts, such asCandidaorMalassezia. In addition, most cutaneous infections involve itching and may further involve secondary bacterial infection. Depending on the nature of the infection and the patient's symptoms, treatment of cutaneous fungal infections requires consideration of many factors. For example, mixed infections with multiple causes require the use of broad-spectrum anti-infective agents, while symptoms such as itching and secondary bacterial infection require the use of topical remedies with both anti-inflammatory and antipruritic properties.
Sertaconazole nitrate, an imidazole antifungal agent, has demonstrated a broad spectrum of activity against multiple fungal organisms, including dermatophytes and yeasts, such asCandidaandMalassezia. This compound may exhibit fungicidal activity that is not concentration- and organism-dependent. Although sertaconazole 2% cream is approved in the United States for treatment of tinea pedis, multiple studies support its use for other cutaneous dermatophyte infections, cutaneous candidiasis, tinea versicolor, and seborrheic dermatitis. In addition to antifungal activity, sertaconazole nitrate has been shown to exhibit anti-inflammatory and antipruritic activity in multiple laboratory studies. These properties may relate to more rapid reduction in symptoms in the clinical setting. Understanding these unique properties of sertaconazole may improve patient care in the treatment of superficial fungal infections.
By reading and studying this supplement, participants should be prepared to:
• Name three organisms that are targeted by sertaconazole.
• Describe the anti-inflammatory and antibacterial properties of sertaconazole.
• Discuss the clinical trial results of sertaconazole for the treatment of a variety of fungal infections, including tinea pedis, tinea versicolor, and intertrigo.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin & Allergy News. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.
The EOCME designated this educational supplement for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Term of Approval: July 2008 - July 31, 2009.
Copyright © 2008 by Elsevier Inc.